IP Library Granted Patent US 7,011,839
Granted Patent B2
US 7,011,839 · App. 10/309,918 · Granted Mar 14, 2006

Otic microbial combination for treatment of animals with ruptured tympanic membrane

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,011,839
App. No.
10/309,918
Granted
Mar 14, 2006
Kind
B2
Abstract

Disclosed herein is an improved composition that is useful in treating otic infections comprising an antimicrobial and silver sulfadiazine in a therapeutically effective combination to treat otic infections in animals, the improvement comprising the composition which can be used safely to treat animals with a ruptured tympanic membrane.

Claims (15)

1. An improved method of treating an otic infection in an animal comprising administering a composition comprising an antimicrobial and silver sulfadiazine in a therapeutically effective combination to treat the otic infection, the improvement comprising administering the composition to an animal with a ruptured tympanic membrane.

2. The method of claim 1 , wherein said composition is administered in a pharmaceutically effective amount.

3. The method of claim 1 , wherein said composition is administered on a twice daily basis.

4. The method of claim 1 , wherein said enrofloxacin is present in an amount from about 0.005 to about 1.5 percent by weight of the composition.

5. The method of claim 4 , wherein said enrofloxacin is present in an amount from about 0.1 to about 1.0 percent by weight of the composition.

6. The method of claim 1 , wherein said silver sulfadiazine is present in an amount from about 0.05 to about 2.0 percent by weight of the composition.

7. The method of claim 6 , wherein said silver sulfadiazine is present in an amount from about 0.5 to about 1.5 percent by weight of the composition.

8. The method of claim 1 , wherein said composition further comprises a physiologically acceptable carrier.

9. The method of claim 8 , wherein said carrier comprises an emulsion.

10. The method of claim 9 , wherein said emulsion comprises and oil in water emulsion.

11. The method of claim 10 , wherein said oil is selected from the group consisting of mineral oil, vegetable oil and reformed vegetable oil.

12. The method of claim 11 , wherein said oil is selected from the group consisting of peanut oil, sesame seed oil, cotton seed oil, and medium chain triglycerides.

13. The method of claim 9 , wherein said emulsion comprises an emulsifier that is present in an amount of about 1.5 to about 6.5 percent by weight of the composition.

14. The method of claim 13 , wherein said emulsifier is selected from the group consisting of sorbitan monostearate and polysorbate 60.

15. The method of claim 9 , wherein said emulsion comprises a non-aqueous phase in an amount of about 15 to about 25 percent by weight of the composition.

Assignments (3)
ASSIGNMENT OF SECURITY INTEREST IN PATENT RIGHTS, RECORDED ON OCTOBER 29, 2020, AT REEL/FRAME 054217/0148 Recorded Dec 3, 2025
From: GOLDMAN SACHS BANK USA, AS RETIRING COLLATERAL AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 073816/0043 →
SECURITY INTEREST Recorded Oct 29, 2020
From: ELANCO US INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 054217/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2020
From: BAYER HEALTHCARE LLC
To: ELANCO US INC.
Reel/Frame 054023/0286 →